Caprock Group’s 10x Genomics TXG Stock Holding History

Caprock Group’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.96M	Sell	155,444 -26,378	-15%	-$691K	0.11%	138
2026 Q1	$3.86M	Sell	181,822 -9,091	-5%	-$182K	0.09%	191
2025 Q4	$3.11M	Buy	190,913 +71,110	+59%	+$1.07M	0.07%	257
2025 Q3	$1.68M	Buy	+119,803	New	+$1.56M	0.04%	407

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caprock Group's TXG Position: Q2 2026 in Review

Caprock Group reduced its 10x Genomics (TXG) stake by 15% in Q2 2026, selling an estimated $691K and leaving 155,444 shares worth $5.96M. The position accounts for 0.11% of the portfolio, ranked #138.

Caprock Group first reported a position in TXG in Q3 2025 and has held it in 4 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Caprock Group held 155,444 shares of 10x Genomics worth $5.96M as of Q2 2026.
Caprock Group sold 26,378 10x Genomics shares in Q2 2026, an estimated $691K.
10x Genomics made up 0.11% of Caprock Group's portfolio in Q2 2026, its #138 holding.
Caprock Group first reported a position in 10x Genomics in Q3 2025 and has held it in 4 quarters since.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.